Exploring High Growth Tech Stocks in December 2024

Simply Wall St.12-05

Over the last 7 days, the United States market has risen 1.4% and is up an impressive 34% over the last 12 months, with earnings expected to grow by 15% per annum in the coming years. In this thriving...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489469568?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2024-12-05 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489469568","market":"us","top_or_hot":-1,"title":"Exploring High Growth Tech Stocks in December 2024","media":"Simply Wall St.","content":"<div>\n<p>Over the last 7 days, the United States market has risen 1.4% and is up an impressive 34% over the last 12 months, with earnings expected to grow by 15% per annum in the coming years. In this thriving...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/exploring-high-growth-tech-stocks-in-december-2024-2\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exploring High Growth Tech Stocks in December 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExploring High Growth Tech Stocks in December 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-05 22:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/exploring-high-growth-tech-stocks-in-december-2024-2><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Over the last 7 days, the United States market has risen 1.4% and is up an impressive 34% over the last 12 months, with earnings expected to grow by 15% per annum in the coming years. In this thriving...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/exploring-high-growth-tech-stocks-in-december-2024-2\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXAS","symbol_name":"精密科学","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/exploring-high-growth-tech-stocks-in-december-2024-2","article_id":"2489469568","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489469568","pubTimestamp":1733407362,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Over the last 7 days, the United States market has risen 1.4% and is up an impressive 34% over the last 12 months, with earnings expected to grow by 15% per annum in the coming years. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable market conditions.","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"EXAS":"精密科学","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0079474960.USD":"联博美国增长基金A","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4588":"碎股","VRTX":"福泰制药","LU0058720904.USD":"联博国际健康护理基金A","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1861558580.USD":"日兴方舟颠覆性创新基金B","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4548":"巴美列捷福持仓","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","VERX":"Vertex, Inc.","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4532":"文艺复兴科技持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4023":"应用软件","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD"},"translate_title":"探索2024年12月高增长科技股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRTX":0.9,"VERX":0.9,"EXAS":0.9},"content_text":"Over the last 7 days, the United States market has risen 1.4% and is up an impressive 34% over the last 12 months, with earnings expected to grow by 15% per annum in the coming years. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable market conditions.Top 10 High Growth Tech Companies In The United StatesNameRevenue GrowthEarnings GrowthGrowth RatingSuper Micro Computer23.83%24.32%★★★★★★Ardelyx25.47%69.63%★★★★★★Sarepta Therapeutics24.00%42.51%★★★★★★Alnylam Pharmaceuticals22.35%70.33%★★★★★★Clene78.50%60.16%★★★★★★TG Therapeutics34.66%56.98%★★★★★★Alkami Technology21.89%98.60%★★★★★★Travere Therapeutics31.70%72.51%★★★★★★Seagen22.57%71.80%★★★★★★ImmunoGen26.00%45.85%★★★★★★Click here to see the full list of 245 stocks from our US High Growth Tech and AI Stocks screener.Let's review some notable picks from our screened stocks.Exact Sciences (NasdaqCM:EXAS)Simply Wall St Growth Rating: ★★★★☆☆Overview: Exact Sciences Corporation is a company that offers cancer screening and diagnostic test products both in the United States and internationally, with a market cap of approximately $11.21 billion.Operations: Exact Sciences generates revenue primarily from its biotechnology segment, contributing approximately $2.69 billion. The company's focus is on cancer screening and diagnostic tests, serving both domestic and international markets.Exact Sciences, a player in the high-stakes field of cancer diagnostics, recently showcased its resilience and innovation at multiple healthcare conferences. Despite a challenging fiscal quarter with sales rising to $708.66 million from $628.34 million year-over-year but facing a net loss increase to $38.24 million from a previous net income of $0.794 million, the company continues to invest heavily in research and development (R&D). This dedication is evident as R&D expenses surged by 9.2%, underscoring its commitment to pioneering advanced diagnostic solutions like the FDA-approved Cologuard Plus test, which outperformed traditional tests in detecting colorectal cancer with 95% sensitivity. Looking ahead, Exact Sciences anticipates leveraging its robust product pipeline and commercial infrastructure to enhance cancer screening rates across diverse populations, aiming for significant growth in earnings projected at 72.4% annually.Unlock comprehensive insights into our analysis of Exact Sciences stock in this health report.Examine Exact Sciences' past performance report to understand how it has performed in the past.NasdaqCM:EXAS Revenue and Expenses Breakdown as at Dec 2024Vertex (NasdaqGM:VERX)Simply Wall St Growth Rating: ★★★★★☆Overview: Vertex, Inc. offers enterprise tax technology solutions for retail trade, wholesale trade, and manufacturing industries both in the United States and internationally, with a market capitalization of $8.88 billion.Operations: Vertex, Inc. generates revenue primarily through its software and programming segment, which contributes $643.23 million. The company's operations focus on providing tax technology solutions across various industries globally.At the recent Wells Fargo TMT Summit, Vertex showcased its robust fiscal recovery with a notable shift from a net loss to a profit of $7.22 million in Q3 2024, reflecting an impressive turnaround. This performance is underpinned by strategic innovations such as the integration of Vertex for Salesforce Revenue Cloud, which enhances tax compliance and operational efficiency for businesses. With R&D expenses climbing by 14.2%, Vertex is significantly investing in technology that drives these advancements. The company's forward-looking revenue guidance suggests continued growth, projecting up to $666.3 million by year-end, supported by an expected annual profit growth rate of 42.6%. This trajectory indicates Vertex's potential to outperform market expectations and solidify its foothold in transformative tech solutions.Click to explore a detailed breakdown of our findings in Vertex's health report.Understand Vertex's track record by examining our Past report.NasdaqGM:VERX Earnings and Revenue Growth as at Dec 2024Nutanix (NasdaqGS:NTNX)Simply Wall St Growth Rating: ★★★★★☆Overview: Nutanix, Inc. offers an enterprise cloud platform across various global regions including North America, Europe, the Asia Pacific, the Middle East, Latin America, and Africa with a market capitalization of approximately $17.68 billion.Operations: Nutanix generates revenue primarily from its Internet Software & Services segment, amounting to approximately $2.23 billion. The company focuses on providing a comprehensive enterprise cloud platform across multiple global regions.Nutanix's recent transition from a net loss to a net income of $29.93 million in Q1 2025 underscores its robust financial recovery, with revenue climbing to $590.96 million from $511.05 million year-over-year, showcasing a significant growth trajectory. This performance is bolstered by the company's strategic advancements in AI technologies, notably through its new Nutanix Enterprise AI platform which supports hybrid multi-cloud operations and accelerates deployment of generative AI applications across diverse environments including AWS EKS and Google GKE. With R&D expenses intensifying by 13.1%, Nutanix is deeply investing in innovation to drive these technological enhancements forward, reflecting a clear commitment to evolving its offerings in line with emerging tech trends.Dive into the specifics of Nutanix here with our thorough health report.Learn about Nutanix's  historical performance.NasdaqGS:NTNX Revenue and Expenses Breakdown as at Dec 2024Summing It All UpNavigate through the entire inventory of 245 US High Growth Tech and AI Stocks here.Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.Curious About Other Options?Explore high-performing small cap companies that haven't yet garnered significant analyst attention.Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.Find companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data \n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your \n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data. \n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. \n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Exact Sciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489469568"}